• Ampicillin Sodium: Applied Workflows for Antibacterial Assay

  2026-07-02

  Ampicillin sodium excels as a β-lactam antibiotic for robust antibacterial activity assays, streamlining both in vitro screening and advanced infection model workflows. This article dissects protocol enhancements, comparative advantages, and actionable troubleshooting strategies to maximize reproducibility in antibiotic resistance and bacterial cell wall biosynthesis inhibition research.

• KPT-330 Inhibits Osteoclastogenesis to Alleviate Osteoarthri

  2026-07-02

  This study demonstrates that KPT-330 (Selinexor), a selective CRM1 inhibitor, mitigates osteoarthritis progression by suppressing subchondral bone osteoclastogenesis through the NF-κB and MAPK pathways. The findings highlight a novel application of nuclear export inhibition beyond oncology, suggesting dual-action disease modification in osteoarthritis.

• Drug-Sensitized Yeast Enables Sensitive mTOR Inhibitor Disco

  2026-07-01

  A recent study introduces a refined yeast-based platform with enhanced drug sensitivity, offering a robust method for identifying inhibitors of the mTOR pathway. This innovation significantly increases detection sensitivity for TOR inhibitors, facilitating rapid, cost-efficient screening and informing future therapeutic research.

• Rimonabant (SR141716): Selective CB1 Antagonist for Appetite

  2026-07-01

  Rimonabant (SR141716) is a highly selective CB1 receptor antagonist with strong efficacy in modulating endocannabinoid signaling. Evidence confirms its utility in appetite regulation research and preclinical models of cannabinoid withdrawal. Its specificity and solubility profile make it a preferred tool for mechanistic obesity and neurobiology studies.

• Deep Learning Detects Cardiotoxicity in iPSC-Derived Cardiom

  2026-06-30

  This study introduces a deep learning-based imaging workflow to rapidly identify cardiotoxic compounds using human iPSC-derived cardiomyocytes. The approach enables scalable, early-stage detection of drug-induced cardiac risk, offering a new standard for phenotypic screening in preclinical drug development.

• TRIM21 Drives ERK1/2-Mediated Proliferation and Resistance i

  2026-06-30

  This study elucidates how TRIM21 promotes pituitary adenoma cell proliferation and drug resistance through ubiquitination and phosphorylation of ERK1/2. The findings highlight TRIM21 as a novel therapeutic target, with evidence supporting the use of HDAC inhibitors such as Quisinostat to modulate this pathway and potentially overcome drug resistance in pituitary tumors.

• AI-10-49: CBFβ-SMMHC Inhibitor Transforming AML Research

  2026-06-29

  AI-10-49, a highly selective CBFβ-SMMHC inhibitor, is reshaping acute myeloid leukemia (AML) research by restoring RUNX1 function and disrupting oncogenic signaling. This article guides researchers through optimized workflows, practical troubleshooting, and the latest experimental advances enabled by this compound.

• Cinoxacin in Quinolone Antibiotic Research: Workflows & Solu

  2026-06-29

  Cinoxacin offers robust, data-backed performance in gram-negative urinary tract infection research and antibiotic resistance modeling. This guide translates foundational studies and advanced protocols into actionable workflows for microbiology labs, highlighting troubleshooting strategies and comparative advantages unique to Cinoxacin from APExBIO.

• Nigericin: Potassium/Hydrogen Ion Carrier for Experimental P

  2026-06-28

  Nigericin’s unique role as a potassium/hydrogen ion carrier enables researchers to precisely modulate intracellular pH and disrupt mitochondrial ion gradients, advancing both cancer and antimicrobial studies. This article delivers actionable protocols, troubleshooting insights, and translational context, bridging recent metabolic findings with applied laboratory workflows.

• Cefodizime: Broad-Spectrum Activity and Clinical Efficacy Re

  2026-06-27

  This literature review systematically evaluates cefodizime, a third-generation cephalosporin antibiotic, highlighting its broad-spectrum antibacterial activity, favorable pharmacokinetics, and immunomodulatory effects. The findings support its utility for respiratory and urinary tract infections, with clinical evidence pointing to high cure rates, convenient dosing, and reliable tolerability.

• Linezolid (SKU A5181): Oxazolidinone Antimicrobial for Relia

  2026-06-26

  This article delivers a scenario-driven, evidence-based guide for researchers deploying Linezolid (SKU A5181) in cell viability, proliferation, and cytotoxicity assays. Drawing on real laboratory challenges and validated quantitative data, it demonstrates how Linezolid’s reproducible inhibition of bacterial protein synthesis makes it indispensable for Gram-positive antimicrobial workflows. Emphasis is placed on protocol optimization, data interpretation, and supplier reliability, ensuring that researchers can confidently integrate this oxazolidinone antimicrobial into their experimental pipelines.

• Cefodizime: Third-Generation Cephalosporin Workflows in Micr

  2026-06-26

  Cefodizime, a third-generation cephalosporin antibiotic from APExBIO, excels in broad-spectrum bacterial research, offering reproducibility and β-lactamase stability. This guide delivers actionable protocols, troubleshooting insights, and data-driven workflow enhancements for antimicrobial studies focused on respiratory and urinary tract pathogens.

• Z-VEID-FMK: Precision Caspase-6 Inhibitor for Apoptosis Assa

  2026-06-25

  Z-VEID-FMK empowers researchers to selectively dissect caspase-6-dependent apoptosis pathways with unrivaled specificity, especially in neuroinflammation and pain models. This article translates recent preclinical breakthroughs and hands-on workflow enhancements into actionable, lab-ready guidance.

• TMRE Mitochondrial Membrane Potential Assay Kit: Applied Ins

  2026-06-25

  The TMRE mitochondrial Membrane Potential Assay Kit empowers researchers to unravel mitochondrial physiology and cell fate by delivering high-throughput, quantitative detection of ΔΨm changes. This guide bridges advanced ion-driven research, cutting-edge protocol optimization, and troubleshooting with current breakthroughs in sodium-induced mitochondrial dysfunction.

• Pravastatin Sodium: Molecular Mechanisms and Transporter Dyn

  2026-06-24

  Explore the molecular pharmacology of Pravastatin sodium, a leading HMG-CoA reductase inhibitor, with a focus on transporter-mediated uptake and assay design. This article delivers new insights for cholesterol biosynthesis inhibition and drug interaction prediction.

16362 records 1/1091 page Next 12345 下5页 Last page